HIV-1 infection of human penile explant tissue and protection by candidate microbicides

AIDS

Volumn 23, Issue 3, 2009, Pages 319-328

  Fischetti, Lucia ^a   Barry, Sheila M ^b   Hope, Thomas J ^b   Shattock, Robin J ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Foreskin; Glans; HIV 1; Microbicide; Tissue explant

Indexed keywords

CYANOVIRIN N; CYTOKINE; GAG PROTEIN; MICROBICIDE; POLY(METHYL 2 PROPIONAMIDOACRYLATE; POLY(METHYL 2 PROPIONAMIDOACRYLATE); POLYMER; PRO 2000; T6 ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BIOCOMPATIBILITY; CD4+ T LYMPHOCYTE; CELL DENSITY; CELL MIGRATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CIRCUMCISION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DISEASE MODEL; DISEASE TRANSMISSION; DRUG EFFICACY; EXPLANT; GENDER REASSIGNMENT SURGERY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; IMAGING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFECTION PREVENTION; INFECTION SENSITIVITY; MALE; MALE GENITAL SYSTEM SURGERY; MICROSCOPY; PENIS; PENIS GLANS; PREPUCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE CULTURE; URETHRA; VIRUS CULTURE;

ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; FORESKIN; HIV INFECTIONS; HIV-1; HUMANS; LANGERHANS CELLS; MALE; NAPHTHALENESULFONATES; PENIS; POLYMERS; SOMAN; TISSUE CULTURE TECHNIQUES; URETHRA; VIRUS REPLICATION;

EID: 59849108852     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328321b778     Document Type: Article

References (51)

1. WHO. 2007 AIDS epidemic update; 2007.
2. European Study Group on Heterosexual Transmission of HIV. Comparison of female to male and male to female transmission of HIV in 563 stable couples. BMJ 1992; 304:809-813.
3. Hugonnet S, Mosha F, Todd J, Mugeye K, Klokke A, Ndeki L, et al. Incidence of HIV infection in stable sexual partnerships: a retrospective cohort study of 1802 couples in Mwanza Region, Tanzania. J Acquir Immune Defic Syndr 2002; 30:73-80.
4. Nicolosi A, Correa Leite ML, Musicco M, Arid C, Gavazzeni G, Lazzarin A. The efficiency of male-to-female and female-to-male sexual transmission of the human immunodeficiency virus: a study of 730 stable couples. Italian Study Group on HIV Heterosexual Transmission. Epidemiology 1994; 5:570-575.
5. Padian NS, Shiboski SC, Jewell NP. Female-to-male transmission of human immunodeficiency virus. JAMA 1991; 266:1664-1667.
6. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Ser- wadda D, Wabwire-Mangen F, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149-1153.
7. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl I Med 2000; 342:921-929.
8. Serwadda D, Gray RH, Wawer MJ, Stallings RY, Sewankambo NK, Konde-Lule JK, et al. The social dynamics of HIV transmission as reflected through discordant couples in rural Uganda. AIDS 1995; 9:745-750.
9. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. / Infect Dis 2005; 191:1403-1409.
10. Gray RH, Kiwanuka N, Quinn TC, Sewankambo NK, Serwadda D, Mangen FW, et al. Male circumcision and HIV acquisition and transmission: cohort studies in Rakai, Uganda. Rakai Project Team. AIDS 2000; 14:2371-2381.
11. Siegfried N, Muller M, Deeks J, Volmink J, Egger M, Low N, et al. HIV and male circumcision - a systematic review with assessment of the quality of studies. Lancet Infect Dis 2005; 5:165-173.
12. Weiss HA, Quigley MA, Hayes RJ. Male circumcision and risk of HIV infection in sub-Saharan Africa: a systematic review and meta-analysis. AIDS 2000; 14:2361-2370.
13. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2:e298.
14. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Mae circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369:643-656.
15. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalu- goda F, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369:657-666.
16. Wawer MJ, Kigozi G, Serwadda D, Makumbi F, Nalugoda F, Watya S, et al. Trial of male circumcision in HIV+ men, Rakai, Uganda: effects in HIV+ men and in women partners. 75th Conference on Retroviruses and Opportunistic Infections; 2008; Boston, MA, United States.
17. Turner AN, Morrison CS, Padian NS, Kaufman JS, Salata RA, Chipato T, et al. Men's circumcision status and women's risk of HIV acquisition in Zimbabwe and Uganda. AIDS 2007; 21:1779-1789.
18. McCoombe SG, Short RV. Potential HIV-1 target cells in the human penis. AIDS 2006; 20:1491-1495.
19. Patterson BK, Landay A, Siegel JN, Flener Z, Pessis D, Chaviano A, Bailey RC. Susceptibility to human immunodeficiency virus- 1 infection of human foreskin and cervical tissue grown in explant culture. Am I Pathol 2002; 161:867-873.
20. Donoval BA, Landay AL, Moses S, Agot K, Ndinya-Achola JO, Nyagaya EA, et al. HIV-1 target cells in foreskins of African men with varying histories of sexually transmitted infections. Am j Clin Pathol 2006; 125:386-391.
21. Hussain LA, Lehner T. Comparative investigation of Langer- hans' cells and potential receptors for HIV in oral, genitourinary and rectal epithelia. Immunology 1995; 85:475-484.
22. Lederman MM, Offord RE, Hartley O. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat Rev Immunol 2006; 6:371-382.
23. Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 2003; 1:25-34.
24. Watts C, Kumaranayake L, Vickerman P, Terris-Prestholt F. The public health benefits of microbicides in lower-income countries. Public Health Working Croup. New York: Rockefeller Foundation; 2002.
25. Fletcher PS, Wallace GS, Mesquita PM, Shattock RJ. Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants. Retrovirology 2006; 3:46.
26. Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, Shattock RJ. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol 2000; 74:5577-5586.
27. Biancotto A, Grivel JC, Iglehart SJ, Vanpouille C, Lisco A, Sieg SF, et al. Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood 2007; 109:4272-4279.
28. Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2004; 2:33-42.
29. Patterson BK, Landay A, Andersson J, Brown C, Behbahani H, Jiyamapa D, et al. Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. Am I Pathol 1998; 153:481-490.
30. Yeaman CR, Asin S, Weldon S, Demian DJ, Collins JE, Gonzalez JL, et al. Chemokine receptor expression in the human ectocervix: implications for infection by the human immunodeficiency virus-type I. Immunology 2004; 113:524- 533.
31. Zaitseva M, Blauvelt A, Lee S, Lapham CK, Klaus-Kovtun V, Mostowski H, et al. Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. Nat Med 1997; 3:1369- 1375.
32. Kawamura T, Cohen SS, Borris DL, Aquilino EA, Glushakova S, Margolis LB, et al. Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. J Exp Med 2000; 192:1491-1500.
33. David SA, Smith MS, Lopez GJ, Adany I, Mukherjee S, Buch S, et al. Selective transmission of R5-tropic HIV type 1 from dendritic cells to resting CD4+ T cells. AIDS Res Hum Retroviruses 2001; 17:59-68.
34. Granelli-Piperno A, Delgado E, Finkel V, Paxton W, Steinman RM. Immature dendritic cells selectively replicate macropha- getropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-tropic virus to T cells. J Virol 1998; 72:2733-2737.
35. Kawamura T, Gulden FO, Sugaya M, McNamara DT, Borris DL, Lederman MM, et al. R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci USA 2003; 100:8401- 8406.
36. Reece JC, Handley AJ, Anstee E), Morrison WA, Crowe SM, Cameron PU. HIV-1 selection by epidermal dendritic cells during transmission across human skin. J Exp Med 1998; 187:1623-1631.
37. Fahrbach KM, Barry SM, Ayehunie S, Lamore S, Klausner M, Hope TJ. Activated CD34-derived Langerhans cells mediate transinfection with human immunodeficiency virus. l Virol 2007; 81:6858-6868.
38. Turville SG, Santos JJ, Frank I, Cameron PU, Wilkinson J, Miranda-Saksena M, et al. Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood 2004; 103:2170-2179.
39. Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, Sodroski J, et al. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol 2000; 74:1948-1960.
40. Neurath AR, Strick N, Li YY. Anti-HIV-1 activity of anionic polymers: a comparative study of candidate microbicides. BMC Infect Dis 2002; 2:27.
41. Fletcher PS, Shattock RJ. PRO-2000, an antimicrobial gel for the potential prevention of HIV infection. Curr Opin Investig Drugs 2008; 9:189-200.
42. Gallant JE, Staszewski S, Pozniak AL, Dejesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavu- dine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
43. Botos I, O'Keefe BR, Shenoy SR, Cartner LK, Ratner DM, Seeberger PH, et al. Structures of the complexes of a potent anti-HIV protein cyanovirin-N and high mannose oligosaccharides. J Biol Chem 2002; 277:34336-34342.
44. Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH, O'Keefe BR, Mori T, et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother 1997; 41:1521-1530.
45. Tsai CC, Emau P, Jiang Y, Agy MB, Shattock RJ, Schmidt A, et al. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses 2004; 20:11-18.
46. Tsai CC, Emau P, Jiang Y, Tian B, Morton WR, Gustafson KR, Boyd MR. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 2003; 19:535-541.
47. Fletcher PS, Elliott J, Grivel JC, Margolis L, Anton P, McGowan I, Shattock RJ. Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS 2006; 20:1237- 1245.
48. Tabet SR, Callahan MM, Mauck CK, Gai F, Coletti AS, Profy AT, et al. Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men. J Acquir Immune Defic Syndr 2003; 33:476-483.
49. Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 2006; 20:543-551.
50. Balzarini J, Van Herrewege Y, Vermeire K, Vanham G, Schols D. Carbohydrate-binding agents efficiently prevent dendritic cell- specific intercellular adhesion molecule-3-grabbing noninte- grin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol Pharmacol 2007; 71:3-11.
51. Balzarini J, Van Laethem K, Peumans WJ, Van Damme EJ, Bolmstedt A, Gago F, Schols D. Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J Virol 2006; 80:8411-8421.